Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

Background Three classes of inhaler medications are used to manage chronic obstructive
pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic …

Background Current guidelines recommend the use of inhaled corticosteroids (ICSs) added
to long-acting β 2-agonists (LABAs) for treatment of symptomatic patients with severe and …

Background Inhaled corticosteroid (ICS)/long-acting β 2 agonist (LABA) fixed-dose
combinations (FDCs) and LABA/long-acting muscarinic antagonist (LAMA) FDCs are …

Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic
antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been …

Purpose To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs),
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …

Background Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-
acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic …

Background The place of long-acting β agonist/long-acting muscarinic antagonist
(LABA/LAMA) combinations in stable patients with COPD is not well defined. The purpose of …